

Date: December 15, 2023

BSE Limited

P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Script Code: 543904

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Intimation of investment in Actimed Therapeutics Limited

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we would like to inform that the Company has made investment of GBP 999,900 in Actimed Therapeutics Limited ("Actimed") on December 15, 2023.

The detailed disclosure as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 for aforesaid is enclosed as annexure I.

You are requested to kindly take the above information on your records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

Pradeep Chugh
Company Secretary and Compliance Officer
Membership No. A18711

Annexure I

Disclosure as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Sr. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc	Name: Actimed Therapeutics Limited (“Actimed”) Turnover as on December 31, 2022: GBP 797,919
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	The acquisition would not fall within the related party transactions and it is on arm’s length basis. The Promoters / promoter group / group companies are not interested in the transaction.
3.	Industry to which the entity being acquired belongs	Pharmaceutical Industry
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	It is a strategic investment in the field of treatment of cancer cachexia, amyotrophic lateral sclerosis and other muscle wasting disorders.
5.	Brief details of any governmental or regulatory approvals required for the acquisition;	Not Applicable
6.	Indicative time period for completion of the acquisition	Not Applicable
7.	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash consideration
8.	Cost of acquisition and/or the price at which the shares are acquired	GBP 999,900
9.	Percentage of shareholding / control acquired and / or number of shares acquired	This additional investment has been made for acquiring ~1.29% of the paid-up ordinary share capital of Actimed. Post this investment the aggregate shareholding of the Company in Actimed will be ~10.19%.

MANKIND PHARMA LIMITED



10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>Actimed was incorporated in United Kingdom on December 9, 2016. It is a clinical stage biopharmaceutical company working on the treatment of cancer cachexia, amyotrophic lateral sclerosis (ALS) and other muscle wasting disorders.</p> <p>Last three years turnover of Actimed are as follows;</p> <table border="1" data-bbox="550 504 1204 645"><thead><tr><th>Year</th><th>Turnover</th></tr></thead><tbody><tr><td>December 31, 2022</td><td>GBP 797,919</td></tr><tr><td>December 31, 2021</td><td>GBP 1,423,408</td></tr><tr><td>December 31, 2020</td><td>Nil</td></tr></tbody></table>	Year	Turnover	December 31, 2022	GBP 797,919	December 31, 2021	GBP 1,423,408	December 31, 2020	Nil
Year	Turnover									
December 31, 2022	GBP 797,919									
December 31, 2021	GBP 1,423,408									
December 31, 2020	Nil									